



Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/804,392
Filing Date	March 19, 2004
First Named Inventor	Ferrone et al.
Group Art Unit	1644
Examiner Name	VanderVegt
Attorney Docket Number	03551.0154

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
IPV/	1	CHAPMAN et al. <i>Immunization of Melanoma Patients with Antiidiotypic Monoclonal Antibody BEC2 (Which Mimics GD3 Ganglioside): Pilot Trials Using No Immunological Adjuvant</i> , Vaccine Research (1994) Vol. 3, No. 2, pp. 59-69	
	2	GRANT et al. <i>Long Survival of Patients with Small Cell Lung Cancer After Adjuvant Treatment with the Anti-Idiotypic Antibody BEC2 Plus Bacillus Calmette-Guerin<sup>1</sup></i> , Clinical Cancer Research (June 1999) Vol. 5, pp. 1319-1323	
	3	LESINSKI et al. <i>A DNA Vaccine Encoding a Peptide Mimic of Streptococcus Pneumoniae Serotype 4 Capsular Polysaccharide Induces Specific Anti-Carbohydrate Antibodies in Balb/c Mice</i> , Vaccine (2001) Vol. 19, pp. 1717-1726	
	4	LUO et al. <i>A Molecular Basis for Functional Peptide Mimicry of a Carbohydrate Antigen</i> , The Journal of Biological Chemistry (May 26, 2000) Vol. 275, No. 21, pp. 16146-16154	
	5	McCAFFERY et al. <i>Immunization of Melanoma Patients with BEC2 Anti-Idiotypic Monoclonal Antibody that Mimics GD3 Ganglioside: Enhanced Immunogenicity When Combined with Adjuvant</i> , Clinical Cancer Research (April 1996) Vol. 2, pp. 679-686	
	6	MITTELMAN et al. <i>Human High Molecular Weight Melanoma-Associated Antigen (HMW-MAA) Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Induction of Humoral Anti-HMW-MAA Immunity and Prolongation of Survival in Patients with Stage IV Melanoma</i> , Proc. Natl. Acad. Sci. (January 1992) Vol. 89, pp. 466-470	

Examiner Signature	/F. Pierre VanderVegt/	Date Considered	04/25/2007
-----------------------	------------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Translation is attached.

Burden Hour Statement: The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.